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Abstract 
Background: Lewy body disease is postulated, by the Braak model, to originate in the enteric nervous 
system, before spreading to the central nervous system. Therefore, a high prevalence of gastroparesis 
symptoms would be expected in prodromal dementia with Lewy bodies (DLB) and be highest in those 
with a dopaminergic deficit on imaging.  The aim of this study was to explore whether gastroparesis 
was an early diagnostic marker of prodromal DLB and explore the relationship between symptoms 
and dopaminergic imaging findings on FP-CIT SPECT. 
 
Methods: We recruited 75 patients over 60 with mild cognitive impairment (MCI);, 48 with MCI with 
suspected Lewy body disease (MCI-LB) and 27 with MCI with suspected Alzheimer’s disease (MCI-AD). 
All patients completed the Gastroparesis Cardinal Symptom Index (GSCI) questionnaire and also 
underwent FP-CIT [123I-N-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)] dopaminergic imaging.  
 
Results: At least one symptom suggestive of gastroparesis was reported in 48% (n=23) MCI-LB vs 37% 
MCI-AD (n=10) (P=0.36). Rates of definite symptoms of gastroparesis, as defined by a GCSI Total score 
≥ 1.90, were rare and rates in MCI-LB were not different from MCI-AD (6% vs 0%, p=0.55). After 
adjusting for gender differences between groups, no difference in gastroparesis symptom prevalence 
(2.27 vs 0.81 P=0.05) or severity score (0.62 vs 0.28, p= 0.28) was noted between normally and 
abnormally visually rated FP-CIT SPECT scans.     
 
Conclusion: The GCSI is not a useful tool for differentiating MCI-LB from MCI-AD. A low rate of definite 
gastroparesis was detected in prodromal DLB. No association was found between gastroparesis 
symptoms and FP-CIT SPECT findings.  
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Commented [AY1]: This is significant? 
3 
Running title: Gastroparesis in Prodromal DLB 
Background 
Prodromal dementia refers to a symptomatic pre-dementia stage before the development of the 
dementia syndrome. Mild cognitive impairment with Lewy bodies (MCI-LB) is synonymous with 
prodromal dementia with Lewy Bodies (DLB). It is characterised by the diagnosis of mild cognitive 
impairment and the presence of diagnostic symptoms of Lewy body disease (visual hallucinations, 
parkinsonism, cognitive fluctuations and rapid eye movement (REM) sleep behaviour disorder) as 
defined by consensus criteria [1].  
  
Gastrointestinal (GI) dysfunction is common in Lewy body (LB) disease and has been investigated 
predominately in Parkinson’s disease (PD) populations, with up to 45% of PD subjects having upper GI 
symptoms such as bloating, nausea, and vomiting [2-4]. GI dysfunction can be an early pre-motor 
symptom in PD and worsen with disease progression [3]. The recent incorporation of constipation into 
the research criteria as a marker of prodromal PD has highlighted the early involvement of the gut in 
Lewy body disease [5].  However, the specific prevalence of gastrointestinal symptoms in prodromal 
DLB is a relatively understudied topic and whether the presence of gastrointestinal symptoms could 
be utilised as an early diagnostic marker of cognitive impairment due to LB disease has not previously 
been studied [6].  
 
Gastroparesis is a syndrome characterised by delayed gastric emptying in the absence of structural 
gut abnormality. Gastroparesis is either idiopathic or secondary to a variety of co-morbidities or 
medications. In LB disease, involvement of the enteric nervous is thought to be responsible for delayed 
gastric motility. Patients present with predominately upper GI symptoms of nausea, vomiting, early 
satiety, postprandial fullness and abdominal distention, although PD patients may also be 
asymptomatic apart from motor fluctuations due to gastric dysmotility. Gastroparesis Cardinal 
Symptom Index (GCSI), is a validated patient-reported symptom assessment instrument of upper 
gastrointestinal symptoms which a patient experiences during the prior two weeks [7]. It is the most 
frequently utilised symptom severity scale for clinical trials in gastroparesis [8] but has not been used 
before to specifically investigate gastroparesis symptoms in a neurodegenerative condition.  
 
Pathologically, the Braak model supports the caudo-rostral progression of Lewy body (LB) pathology, 
with a sequential spread of abnormal alpha-synuclein containing inclusions (Lewy neurites and bodies) 
from the gut to the brain [9-14]. The initial aggregates of alpha-synuclein are postulated to begin in 
the olfactory bulb or the nerve endings surrounding the gastrointestinal tract before ascending via the 
autonomic nerves to the dorsal motor nucleus of vagus and subsequently moving upwards into the 
central nervous system. This model of alpha-synuclein spread explains the high rates of GI dysfunction 
observed in early PD and worsening GI symptoms with PD progression. However, the Braak model is 
insufficient to explain the pathological findings in DLB. LB pathology may be found in the neocortex 
without involvement of the lower brainstem, with no evidence of striatal involvement, and post 
mortem evidence that 10-15% patients with DLB have no significant substantia nigra involvement [15, 
16]. A recent study in an idiopathic REM sleep disorder cohort, a prodromal alpha-synucleinopathic 
condition where nearly all individuals’ progress onto either DLB, PD or multiple system atrophy, 
showed early peripheral autonomic nerve involvement and putaminal dopaminergic deficits 
compared with controls suggesting a caudorostral progression by alpha-synuclein [12]. Our group has 
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recently reported the presence of a dopaminergic deficit in 54% of a prodromal DLB cohort [17]. 
However, we have not previously explored the associations between central dopaminergic findings 
and peripheral autonomic symptoms such as gastroparesis symptoms.       
 
Therefore, the aim of our study was to explore the utility of the GSCI as an early diagnostic marker of 
prodromal DLB in differentiating MCI-LB from MCI-AD. Furthermore, we assessed whether the caudo-
rostral progression of alpha-synuclein from the gut to the brain was evident in a prodromal DLB cohort 
by exploring the association between dopaminergic imaging findings and the symptoms suggestive of 
gastroparesis.  
 
Methods 
 
Participants 
The inclusion criteria for subjects into the study have been previously described [18], in brief we 
recruited subjects based on a diagnosis of MCI made in a memory clinics, elderly medicine and 
neurology clinics in the North East of England and Cumbria. Subjects were ≥ 60 years of age and were 
eligible if they reported at least one clinical symptom associated with DLB, including: autonomic 
symptoms; visual disturbance; olfactory dysfunction and mood changes as well as any indication of 
the presence of core and supportive features of DLB.  
 
All subjects provided written informed consent to take part in the study. The study received ethical 
approval from the National Research Ethics Service Committee North East – Newcastle & North 
Tyneside 2 (Research Ethics Committee Identification Number 12/NE/0290).  
 
Diagnosis 
As described previously [17-19], an expert consensus clinical panel (AT, PD, J-PT) reviewed all the 
clinical assessments data to confirm that subjects met National Institute on Ageing-Alzheimer’s 
Association (NIA-AA) criteria for MCI without considering aetiology [20]. The consensus panel also 
rated the presence or absence or each of the four core clinical LB symptoms characteristic of DLB in 
fourth consensus report of the DLB consortium [cognitive fluctuations, complex visual hallucinations, 
clinical parkinsonism, clinical probable rapid eye movement (REM) sleep behaviour disorder (RBD)] 
[1]. This was performed blind to FP-CIT single photon emission computed tomography (SPECT) results. 
Subjects were allocated to one of three clinical diagnoses: probable MCI-LB, (NIA-AA MCI plus two or 
more of the four clinical core LB symptoms or one of these and an abnormal FPCIT scan), possible MCI-
LB (MCI plus one of the four clinical core symptoms or an abnormal FPCIT scan) and MCI-AD (MCI with 
none of the core these four symptoms, a normal FPCIT scan and evidence of decline which was a 
characteristic of AD with no evidence for another aetiology, i.e they met the additional criterion of 
‘aetiology of MCI consistent with AD pathophysiologic process). The ‘1-year rule’ was applied so that 
no subjects had evidence of Parkinsonism for more than a year before the onset of their cognitive 
decline. Assignment to these diagnostic categories was based on the information from both baseline 
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and annual follow-up clinical evaluations. In this study, the probable MCI-LB and possible MCI-LB were 
grouped together to form a MCI-LB group.  
 
Symptom assessment of Gastroparesis 
The GCSI is a patient rated assessment of symptoms suggestive of gastroparesis and 92% of subjects 
also had a friend or family member present when the assessment was carried out. It is a validated 
questionnaire in people over 18 years of age with a known diagnosis of gastroparesis for at least 6 
months and whom are English speaking. The GCSI consists of three subscales of the Patient 
Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index PAGI-SYM [21], selected to 
measure important symptoms related to gastroparesis: nausea/vomiting, postprandial fullness/early 
satiety, and bloating [7]. A total of 9 questions comprise the GCSI which are subdivided in the three 
subdomains of listed above. If the subject reported the presence of any of the symptoms in the 9 
questions of the GCSI, it was recorded as the presence of a symptom suggestive of gastroparesis. Each 
of the 9 question is rated by the responder according to severity of symptoms, i.e. from 0 to 5 (0= no 
symptoms to 5=severe symptoms) on a Likert scale. The severity score is determined by the average 
score in a subdomain. In brief the three subdomains are constructed as follows; Subdomain 1: Nausea 
or Vomiting (consisting of questions on nausea, retching and vomiting); Subdomain 2: (consisting 
questions on Postprandial fullness or early satiety, Stomach Fullness, Not able to finish a normal-sized 
meal, Feeling excessively full after meals and Loss of appetite); Subdomain 3: (consisting questions on 
Bloating, Stomach visibly larger). 
 
The overall GCSI total score was constructed as the average of the three subdomains scores. GCSI total 
scores ≥ 1.90 were taken as having definite symptoms of gastroparesis. The cut-off at 1.90 was based 
on the original data from Revicki et al [7].   
 
Clinical assessment 
All patients were assessed by the equivalent of a Board Certified Psychiatrist (PCD), who carried out a 
physical and neurological examination. Data regarding demographics, medications, co-morbidities, 
and neuropsychological assessments was also collected.  Quantitative scales were used to assess 
neuropsychiatric symptoms (Geriatric Depression Scale, Neuropsychiatric Inventory (NPI), Mini-
mental State Examination (MMSE), Clinical dementia Rating, Epsworth Sleep Scale, parkinsonism 
(Revised Unified Parkinson’s disease Rating Scale Motor subscale) and level of functional impairment 
(Instrumental Activities of Daily Living Scale) Cumulative Illness Rating Scale for Geriatrics (CIRS-G).  
 
Acquisition of FP-CIT SPECT 
Three to six hours following a bolus intravenous injection of 185 MBq of 123I-FP-CIT (DaTSCAN, GE 
Healthcare, UK), patients were scanned (25 min) using a double-headed gamma camera (Siemens 
Symbia S) fitted with a low-energy high-resolution parallel hole collimator. One hundred and twenty 
(60 per detector) 25 s views over a 360⁰ orbit were acquired on a 128 x 128 matrix with a zoom of 1.23 
x giving a pixel size of 3.9 mm x 3.9 mm. Image processing and display were then performed on a 
Hermes workstation (Hermes Medical Solutions, Stockholm, Sweden). Images were reconstructed 
without attenuation correction using filtered back projection and a Butterworth Filter (order 10, cut-
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off 1.3 cycles/cm). Transverse sections were then manually reoriented to correct for any head tilt and 
to provide a consistent display. 
 
Visual rating of FP-CIT 
As previously described [17], visual assessment of all scans were undertaken blind to clinical diagnosis 
and information by four raters. For the rating session, all scans were independently randomised and 
blinded from clinical data before being presented to each rater. Scans were rated independently by 
each panel member using an established four-category FP-CIT visual rating procedure [22].  All scans 
were rated normal or abnormal and where abnormal were graded 1-3. After rating all scans, any scan 
where there was no complete agreement between all raters was then subsequently reviewed by all 
four raters together where a consensus rating was agreed. 
 
Data analysis 
Analysis of data was performed with SPSS 21.0 statistical analysis software (IBM Inc., USA). 
Demographics and clinical data were compared using Mann-Whitney U tests, Chi-squared and Fisher’s 
Exact tests depending on the nature of the data. Logistic regression modelling was used to control for 
the effects of gender differences between groups and to predict any symptom of gastroparesis in 
subjects with MCI. Odds ratio were estimated with 95% confidence interval and considered significant 
at P<0.05. Due to the exploratory nature of the study, correction for multiple testing was not 
performed.  
 
Results 
A total of 90 subjects consented to the study. However, 15 were excluded from the analysis for the 
following reasons:; withdrew prior to study completion (n=6);, dDementia (n=4), sSubjective cognitive 
impairment/atypical static MCI (n=3);, dDeclined FP-CIT imaging (n=-2).  A total of 75 subjects met all 
criteria and completed baseline assessments including the Gastroparesis Cardinal Symptom Index 
(GSCI) and underwent FP-CIT imaging. Table 1 describes the demographics and clinical characteristics 
of the 75 study participants. There was no difference in demographics between MCI-LB and MCI-AD 
cohorts. As previously described  and consistent with prior published data [17], MCI-LB display higher 
scores in the Hoehn and Yahr scale and part 3 Movement Disorder Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) and had greater impairment on the Instrumental Activities of Daily Living 
(IADL) scale. The MCI-LB group also had higher sleepiness (Epworth Sleepiness Scale), depression 
(Geriatric Depression Scale) and behavioural disturbance (Neuropsychiatric Inventory) [17].  
 
There was no difference between MCI-LB and MCI-AD in the prevalence of co-morbidities or 
medications usage associated with gastroparesis, except for anti-parkinsonian medication usage being 
more prevalent in the MCI-LB group than MCI-AD group, as would be expected (MCI-LB 16.7% vs 0% 
MCI-AD, P<0.05, Fisher’s Exact Test).  The prevalence of co-morbidities known to be associated with 
gastroparesis are listed, namely diabetes (MCI-LB 29% vs 11% MCI-AD, P=0.09), hypothyroidism (MCI-
LB 17% vs 15% MCI-AD, p=1.00) and gastrointestinal dysfunction (MCI-LB 10% vs 7% MCI-AD, p=1.00). 
There was a high prevalence of usage of medications which could impact upon self-reported 
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gastroparesis suggestive symptoms, such as anti-cholinergic drugs (MCI-LB 17% vs 26% MCI-AD, 
p=0.34), anti-dementia drugs (MCI-LB 38% vs 22% MCI-AD, p=0.17) and gastric acid suppressive drugs 
(MCI-LB 54% vs 37% MCI-AD, p=0.15).  
 
Table 1: Clinical characteristics of subjects with MCI groups 
 
 MCI-LB  
(n=48) 
(Mean ± SD) 
MCI-AD  
(n=27) 
(Mean ± SD) 
P-Value 
Age (years) 75.0 ± 8.0 77.6 ± 7.0 U= 562, P=0.18 
Gender (M:F) 31/ 17 (64.6%/35.4%) 11/16 
(40.7%/59.3%) 
Χ2=4.0, df=1 
P=0.12 
MMSE 26.4 ± 2.2 26.3 ± 2.6 U=619, P=0.75 
ACE-R 78.8 ± 9.8 79.9 ± 11.1 U=609, p=0.67 
CDR 0.5 (0.2) 0.4 (0.2) U=643.5, P=0.93 
CIRS-G 9.9 ± 4.8 9.0 ± 3.7 U=580, P=0.45 
IADL 7.3± 1.0 6.2± 1.7 U=291.5, 
P=<0.01* 
UPDRS III 23.0 ± 15.7 14.9 ± 6.4 U467.5, P<0.05* 
H&Y 31/0/8/8/1/0 27/0/0/0/0/0 Χ2= 12.4 df=6, 
<0.01* 
ESS 9.4 ± 5.2 5.2 ± 4.6 U=337.5, <0.01* 
NPI 13.6 ± 10.4 5.9 ± 6.6 U=245.5, 
P=<0.01* 
NPI distress 8.3 ± 7.2 2.5 ± 3.1 U=245.5, 
P=<0.01* 
GDS 4.2 ± 3.5 2.1 ± 1.8 U=375.5, 
P=<0.01* 
Medication at baseline number 
(percentage) 
   
Anti-dementia 38% (n=18) 22% (n=6) Χ2=1.8, df=1, 
P=0.17 
Anti-Parkinsonian 17% (n=8) 0% (n=0) P=<0.05, Fisher 
exact Test 
Antipsychotic 4% (n=2) 0% (n=0) P=0.53, Fisher 
Exact Test 
Antidepressant 38% (n=18) 41% (n=11) Χ2=0.1, df=1, 
P=0.81 
Anticholinergic 17% (n=8) 26% (n=7) Χ2=0.9, df=1 
P=0.34 
Proton pump  
inhibitor/Histamine H2-
receptor antagonists 
54% (n=26) 37% (n=10) Χ2 =2.0, df=1, 
P=0.15 
Co-morbidities    
Diabetes 29% (n=14) 11% (n=3) P=0.09, Fisher 
Exact Test 
Hypothyroidism 17% (n=8) 15% (n=4) P=1.0, Fisher 
Exact Test, 
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GI dysfunction 10% (n=5) 7% (n=2) P=1, Fisher Exact 
Test 
MMSE, Mini-mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination-Revised; CDR, Clinical Dementia Rating scale; CIRS-G, 
Cumulative Illness Rating Scale for Geriatrics; IADL, Instrumental Activities of Daily Living scale; UPDRS; Unified Parkinson’s Disease Rating 
Scale-Part III; H&Y, Hoehn and Yahr; ESS, Epworth Sleepiness Scale; NPI, Neuropsychiatric Inventory; GDS, Geriatric Depression Scale: SD, 
Standard Deviation. 
 
 
Prevalence and Severity of Gastroparesis symptoms between MCI-LB vs MCI-AD  
The prevalence and severity of reported symptoms are shown in Table 2. Very few subjects (n=3) met 
the requirement for definite symptoms of gastroparesis as defined by GCSI score ≥ 1.90 and these all 
belonged to the MCI-LB group (MCI-LB 6% vs 0% MCI-AD, P=0.55, Fisher’s Exact Test). In general, MCI-
LB subjects reported more symptoms suggestive of gastroparesis (MCI-LB 1.5 vs 0.8 MCI-AD, Mann 
Whitney U=555.5, P=0.26), the presence of any symptom suggestive of gastroparesis (MCI-LB 48% vs 
MCI-AD 37%, X2=0.83, P=0.36) and slightly higher overall gastroparesis severity score (MCI-LB 0.4 vs 
0.2 MCI-AD, Mann Whitney U= 562, P=0.30) than MCI-AD but these differences were not significant.  
 
Table 2: Prevalence and mean severity score of symptoms suggestive of gastroparesis between 
MCI-LB vs MCI-AD   
 MCI-LB 
(n=48) 
(%) 
(Mean ± SD) 
MCI-AD 
(n=27) 
(%) 
(Mean ± SD) 
Test Statistic 
 
Nausea (%) 6% (n=3) 7% (n=2) P=0.60,  Fisher 
Exact Test 
Nausea score 0.2 (0.8) 0.3 (0.9) U=639.5, 
P=0.83 
Retching (%) 8% (n=4) 0% (n=0) P=0.29,  Fisher 
Exact Test 
Retching score 0.2 (0.6) N.A. U=594, P=0.13 
Vomiting (%) 4% (n=2) 0% (n=0) P=0.53,  Fisher 
Exact Test 
Vomiting score 0.1 (0.6) N.A. U=621, p=0.29 
Stomach Fullness (%) 17% (n=8) 11% (n=3) P=0.74,  Fisher 
Exact Test 
Stomach fullness score 0.4 (0.9) 0.2 (0.5) U=606, P=0.45 
Not able to finish normal sized meals (%) 21% (n=10) 19% (n=5) X2=0.1, df=1 
P=0.81,  
Not able to finish normal sized meals score 0.5 (1.0) 0.4 (1.0) U=633.5, 
P=0.82 
Feeling Excessively full after meals (%) 21% (n=10) 7% (n=2) P=0.19,  Fisher 
Exact Test 
Feeling Excessively full after meals score 0.4 (0.9) 0.2 (0.7) U=564.5, 
P=0.15 
Loss of appetite (%) 29% (n=14) 19% (n=5) X2=1.0, df=1, 
P=0.31 
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Prevalence and severity of gastroparesis symptoms among MCI-LB groups based on visual 
rating of FP-CIT imaging. 
Table 3 and 4 shows MCI-LB subjects divided into two groups determined by visual assessment of FP-
CIT neuroimaging into normal or abnormal scan findings. There were greater numbers of females in 
the FP-CIT group rated as normal compared to the abnormal FP-CIT group (54.5% vs 19.2%, P=0.01, 
Fisher’s exact test). Overall, there was no difference in the prevalence of any gastroparesis suggestive 
symptoms (Normal FP-CIT 63.6% vs 34.6% Abnormal FP-CIT, adjusted for group gender differences P= 
0.20), absolute numbers of symptoms (Normal FP-CIT 2.3 vs 0.8 Abnormal FP-CIT, adjusted for group 
gender differences P=0.05) or overall symptom severity scores (Normal FP-CIT 0.6 vs 0.3 Abnormal FP-
CIT, adjusted for group gender differences P=0.28) between MCI-LB subjects with normal and 
abnormal visual rating on their FP-CIT after controlling for gender difference between groups. There 
were differences in a few individual symptoms between groups, with bloating (Normal FP-CIT 40.9% 
vs 7.7% Abnormal FP-CIT, adjusted for group gender differences P=0.03) and stomach fullness (Normal 
FP-CIT 31.8% vs 3.8% Abnormal FP-CIT, adjusted for group gender differences P=0.03) being more 
common in the MCI-LB with normally visual rating on FP-CIT. The subdomain 3 severity score 
(corresponding to the mean severity score of the symptoms of bloating and visible stomach 
enlargement) was significantly larger among the MCI-LB subjects with a visibly normally rated FP-CIT 
imaging (Normal FP-CIT 0.9 vs 0.1 Abnormal FP-CIT, adjusted for group gender differences P=0.04).    
 
 
 
Loss of appetite score 0.7 (1.2) 0.5 (1.2) U=583.5, 
P=0.35, 
Bloating (feeling like you need to loosen 
your clothes) (%) 
23% (n=11) 15% (n=4) P=0.55,  Fisher 
Exact Test 
Bloating (feeling like you need to loosen your 
clothes) score 
0.5 (1.1) 0.3 (0.8) U=591.5, 
P=0.37 
Stomach or belly visibly larger (%) 19% (n=9) 4% (n=1) P=0.08,  Fisher 
Exact Test 
Stomach or belly visibly larger score 0.5 (1.0) 0.1 (0.2) U=546, P=0.06 
Any symptom 48% (n=23) 37% (n=10)  X2=0.83, 
P=0.36 
Numbers of symptoms 1.5 ± 2.1  0.8 ± 1.4 U=555.5, 
P=0.26 
Subdomain 1 (nausea/retching/vomiting) 0.2 (0.6) 0.1 (0.3) U=640.5, 
P=0.86 
Subdomain 2 (stomach fullness/not able to 
finish meal/ex full/LOA) 
0.5 (0.8) 0.3 (0.6) U=556, P=0.25 
Subdomain 3 (bloating/stomach larger) 0.5 (1.0) 0.2 (0.4) U=578, P=0.27 
Overall score 0.4 (0.8) 0.2 (0.3) U= 562, 
P=0.30 
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Table 3: Clinical characteristics, co-morbidities and concomitant medications of MCI-LB subjects 
compared by group based on visual rating of FP-CIT imaging  
 MCI-LB –Normal 
visual rating FP-
CIT SPECT 
(n=22) 
(%) 
(Mean ± SD) 
MCI-LB – Abnormal 
visual rating FP-CIT 
SPECT 
(n=26) 
(%) 
(Mean ± SD) 
Test Statistic 
 
Age (years) 74.6 ± 8.9 75.4 ± 7.4 U=271, P=0.76 
Gender (M:F) (% male/%Female) 10/12 (45%/55%) 21/5  
(81%/19%) 
X2 =10.4, df=1, 
P=0.01* 
Medication at baseline number 
(percentage) 
   
Anti-dementia 36% (n=8) 39% (n=10) X2=0.02, df=1, 
P=0.88 
Anti-Parkinsonian 9% (n=2) 23% (n=6) P=0.18, Fisher Exact 
Test 
Antipsychotic 0%  (n=0) 8% (n=2) P=0.29, Fisher Exact 
Test 
Antidepressant 36% (n=8) 39% (n=10) X2=0.02, df=1, 
P=0.88 
Anticholinergic 14% (n=3) 19% (n=5) P=0.61, Fisher Exact 
Test 
Proton pump  
inhibitor/Histamine H2-receptor 
antagonists 
59% (n=13) 50% (n=13) X2 =0.4, df=1, p=0.53 
Co-morbidities    
Diabetes 36% (n=8) 23% (n=6) X2=1.0, df=1,  P=0.31 
Hypothyroidism 27% (n=6) 8% (n=2) P=0.08, Fisher Exact 
Test 
GI dysfunction 18% (n=4) 4% (n=1) P=0.13, Fisher Exact 
Test 
MCI-LB: Mild cognitive impairment with Lewy Bodies 
 
FP-CIT SPECT.:2β-Carbomethoxy-3β- (4-iodophenyl)- N-(3-fluoropropyl)- nortropane single photon emission computed tomography 
 
*P value is significant for across-group comparison; 
 
 
 
 
 
 
 
 
11 
Running title: Gastroparesis in Prodromal DLB 
Table 4: Subject’s prevalence and mean severity score of symptoms suggestive of gastroparesis 
compared by FP-CIT SPECT findings 
 MCI-LB –
Normal visual 
rating FP-CIT 
SPECT 
(n=22) 
(%) 
(Mean ± SD) 
MCI-LB – 
Abnormal 
visual rating 
FP-CIT SPECT 
(n=26) 
(%) 
(Mean ± SD) 
Test Statistic 
 
P-value 
adjusted for 
gender 
difference 
using logistic 
regression 
Nausea (%) 9% (n=2) 4% (n=1) P=0.59, Fisher 
Exact Test 
0.42 
Nausea score 0.3 (0.9) 0.1 (0.6) U=271, P=0.46 0.36 
Retching (%) 14% (n=3) 4% (n=1) P=0.32, Fisher 
Exact Test 
0.17 
Retching score 0.3 (0.7) 0.1 (0.4) U=258, P=0.23 0.17 
Vomiting (%) 5% (n=1) 4% (n=1) P=1.0, Fisher 
Exact Test 
0.59 
Vomiting score 0.2 (0.9) 0.1 (0.2) U-283.5, P=0.88 0.33 
Stomach Fullness (%) 32% (n=7) 4% (n=1) P=0.02*, Fisher 
Exact Test 
0.03* 
Stomach fullness score 0.7 (1.2) 0.1 (0.4) U=206, P=0.01* 0.09 
Not able to finish normal sized 
meals (%) 
27% (n=6) 15% (n=4) P=0.48, Fisher 
Exact Test 
0.75 
Not able to finish normal sized 
meals score 
0.6 (1.1) 0.4 (0.9) U=256, P=0.38 0.95 
Feeling Excessively full after 
meals (%) 
 
32% (n=7) 12% (n=3) P=0.15, Fisher 
Exact Test 
0.25 
Feeling Excessively full after meals 
score 
0.64 (1.1) 0.27 (0.8) U=231.5, P=0.11 0.38 
Loss of appetite (%) 32% (n=7) 27% (n=7) X2=0.1, df=1, 
P=0.71 
0.90 
Loss of appetite score 0.9 (1.4) 0.6 (1.1) U=267, P=0.62 0.69 
Bloating (feeling like you need 
to loosen your clothes) (%) 
41% (n=9) 8% (n=2) P=0.01* Fisher 
Exact Test 
0.03* 
Bloating (feeling like you need to 
loosen your clothes) score 
0.9 (1.3) 0.2 (0.7) U=192.5, P=0.01* 0.05 
Stomach or belly visibly larger 
(%) 
36% (n=8) 4% (n=1) P=0.01*, Fisher 
Exact Test 
0.90 
Stomach or belly visibly larger 
score 
0.9 (1.3) 0.1 (0.4) U=191.5, 
P=<0.01* 
0.03* 
Any symptom 64% (n=14) 35% (n=9) X2=4.02, df=1, 
P=<0.05* 
0.20 
Numbers of symptoms 2.3 ± 2.5 0.8 ± 1.6 U=181.5, P=0.02* 0.05 
Subdomain 1 score 
(nausea/retching/vomiting) 
0.2 (0.8) 0.1 (0.4) U=258.5, P=0.24 0.25 
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Subdomain 2 score (stomach 
fullness/not able to finish 
meal/ex full/LOA) 
0.7 (0.9) 0.3 (0.6) U=218, P=0.12 0.30 
Subdomain 3 score 
(bloating/stomach larger) 
0.9 (1.3) 0.1 (0.5) U=186.5, 
P=<0.01* 
0.04* 
Overall mean severity score 0.6 (0.7) 0.3 (0.8) U=182.5, P=0.02* 0.28 
MCI-LB: Mild cognitive impairment with Lewy Bodies 
 
FP-CIT SPECT.:2β-Carbomethoxy-3β- (4-iodophenyl)- N-(3-fluoropropyl)- nortropane single photon emission computed tomography 
 
*P value is significant for across-group comparison;  
  
 
Logistic Regression of factors affecting symptoms of gastroparesis in the whole MCI cohort 
A logistic regression model was developed to predict symptoms suggestive of gastroparesis in the MCI 
cohort as a whole. The logistic regression model allowed for the exploration of the contribution of 
medications and co-morbidities to gastroparesis symptom prevalence. Age, gender, co-morbidities, 
medications, visually rated FP-CIT imaging outcome were used. The model was significant (p=0.01) 
and correctly categorised 68% of study participants. Only female gender emerged as significant 
independent predictor of any gastroparesis symptoms: OR 4.44, 95% CI 1.39 -14.21, p=0.01.  
Gastroparesis symptom outcome was not predicted by abnormal visually rated FP-CIT: OR 0.72, 95% 
CI 0.24-2.19, p=0.56.; or medications (OR 2.97, 95% CI 0.90 -9.85, p=0.08) or co-morbidities (OR 0.55, 
95% CI 0.19 -1.63, p=0.28).  
 
Discussion 
In the present study, we investigated the prevalence of symptoms suggestive of gastroparesis in 
patients at the MCI-LB stage and assessed the GCSI utility at differentiating MCI-LB from MCI-AD.  We 
also explored the association between dopaminergic FP-CIT imaging findings and the prevalence of 
symptoms of gastroparesis.  
 
We found only a low rate indicative of definite symptoms of gastroparesis in the MCI-LB group (6%) 
and no evidence of definite symptoms of gastroparesis. A substantial proportion of both the MCI-LB 
(48%) and MCI-AD (37%) reported the presence of least one symptom suggestive of gastroparesis but 
there was no difference between MCI-LB and MCI-AD cohorts in terms of the prevalence of any upper 
GI symptoms or absolute number of symptoms suggestive of gastroparesis. Gastric acid suppressing 
agent usage, which could reduce upper GI symptomatology, was substantial in both the MCI-LB group 
and MCI-AD group but was not significantly between groups. The level of utilisation of these 
medications in similar aged population groups is consistent with reported levels in the literature [23]. 
Based on the findings of this study, the GSCI is not a useful tool to differentiate MCI-LB from MCI-AD.  
 
LB disorders are recognised to be a multisystem disorder affecting not only the central nervous system 
but also the peripheral nervous system. Based on the Braak model of the hypothesised spread of 
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alpha-synuclein in LB disease, gastrointestinal features should be an early manifestation of LB disease. 
The vagus nerve has a central role in the control of gastric emptying and is affected early with alpha-
synuclein involvement of the dorsal motor nucleus of vagus before subsequent ascent to the 
brainstem [13, 14].  Therefore, we had hypothesised that subjects with MCI-LB in conjunction with a 
dopaminergic deficit on a FP-CIT SPECT would experience more symptoms suggestive of gastroparesis 
than those MCI-LB with a normal FP-CIT SPECT. However, the application of FP-CIT as a biomarker in 
conjunction with the GCSI tool among the MCI-LB group showed no difference in self-reported 
gastroparesis symptoms between those with a normal rated imaging versus those with abnormally 
rated imaging, in terms of symptom prevalence, absolute numbers of symptoms or overall symptom 
severity scores. Conversely, stomach fullness and bloating were more commonly reported in those 
with normal FP-CITs than those with abnormal FP-CITs scans but the mean symptom severity score 
was no different for these two symptoms across the groups. The overall findings do not support the 
Braak model of sequential alpha-synuclein spread in prodromal DLB but caution must be applied in 
the interpretation of the results as there is relatively small numbers in each groups and the MCI-LB 
group needs to follow-up prospectively to determine if they convert to DLB.   
 
To the best of our knowledge, no assessment of gastroparesis or delayed gastric emptying prevalence 
have been reported to date at the dementia or at the pre-dementia stage.  However, impaired gastric 
motility has been investigated in other neurodegenerative associated with LB pathology, namely PD, 
and appears to present early in the disease course of PD but does not correlate well with advancing 
disease [2, 4, 24]. A recent review on this topic report that 15 studies had investigated the prevalence 
of delayed gastric emptying in PD, six using the gold standard method of gastric scintigraphy and nine 
using 13C-octanoate breath tests [24]. There has been no reports on the utilisation of the GSCI in PD. 
The true prevalence of delayed gastric emptying in PD remains controversial, with more marked rates 
observed in breath tests studies than in the gold standard gastric scintigraphy studies. The prevalence 
of delayed gastric emptying in PD has been shown to be high between 70-100% [4]. However, there 
has been a lack of correlation between delayed gastric emptying and upper GI symptoms in PD [4]. 
Therefore the prevalence of symptomatic gastroparesis (delayed gastric emptying in the presence of 
upper GI symptoms) in PD is unknown [4]. 
 
Several factors independent of LB disease may affect the prevalence and the severity of self-reported 
symptoms of gastroparesis. A number of factors have independently been associated with reduced 
gastroparesis symptoms including; male sex, age 50 years and older, antidepressant use [25]. We do 
not believe any of these factors contributed to the low rates of definite gastroparesis found in our 
study. Firstly, participants had to be aged at least 60 years old as part of our inclusion criteria and 
there was no difference between MCI-LB and MCI-AD groups in terms of gender or antidepressant 
therapy. Among the MCI-LB group subdivided based on the visual assessment of their FP-CIT imaging, 
those with normal FP-CIT imaging had significantly more females than the abnormal FP-CIT imaging. 
Before controlling for the gender difference between groups, a greater absolute number of symptoms 
and overall mean severity score symptoms were reported in the normal FP-CIT group which had 
predominately more females, but this was lost after controlling for gender.  We also examined the 
role of co-morbidities and medications in being independent predictive of any gastroparesis symptom 
using a logistic regression model as both co-morbidities and medications are known to affect symptom 
prevalence of gastroparesis  [2, 26]. However, we found that co-morbidities and medications were not 
independent predictors of gastroparesis symptom prevalence. 
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This study has a number of limitations. Firstly, gastrointestinal symptoms are relatively common 
complaints amongst the elderly and are not specific for a given condition. Secondly, GSCI is used only 
to imply that the symptoms reported are suggestive of gastroparesis but delayed gastric emptying 
may still be present in the absence of symptoms and would require gastric scintigraphy to evaluate 
the gastric emptying rate [27]. Therefore, it is entirely possible that patients may be asymptomatic 
and a more extensive investigation with gastric scintigraphy may reveal a subclinical slowed gastric 
transit. Thirdly, this is relatively small study populations and caution must be exercised in its 
interpretation of results as the small groups required the application of non-parametric statistical 
testing for inferring between-group differences. 
 
Conclusion 
The findings of this study suggests that GSCI is not a useful tool for differentiating MCI-LB from MCI-
AD. The presence of definite gastroparesis, as detected by the GCSI, is low in prodromal DLB and there 
no association between gastroparesis symptoms prevalence or severity and dopaminergic imaging 
findings on FP-CIT SPECT.  
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